兴齐眼药(300573) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 286,560,377.99, a decrease of 5.10% compared to CNY 301,958,988.82 in the same period last year[4] - Net profit attributable to shareholders was CNY 19,349,332.43, down 73.91% from CNY 74,168,573.48 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 15,561,733.77, a decrease of 79.32% compared to CNY 75,262,091.90 in the previous year[4] - Basic and diluted earnings per share were both CNY 0.22, a decrease of 73.81% from CNY 0.84 in the previous year[4] - Net profit for the period was CNY 22,867,144.85, down 74.0% from CNY 87,958,734.62 in Q1 2022[19] - The net profit for Q1 2023 was CNY 19,349,332.43, a significant improvement compared to a net loss of CNY 74,168,573.48 in the same period last year, representing a turnaround of approximately 126%[20] - The company reported a decrease in sales revenue from CNY 313,334,689.40 in Q1 2022 to CNY 283,170,181.44 in Q1 2023, a decline of about 9.6%[21] Cash Flow and Assets - The net cash flow from operating activities was CNY 58,337,902.67, down 43.53% from CNY 103,314,893.79 in the same period last year[4] - Cash and cash equivalents at the end of the quarter were CNY 485,537,595.56, a decrease from CNY 515,449,608.39 at the beginning of the year[18] - Total cash and cash equivalents at the end of Q1 2023 were CNY 484,149,429.77, down from CNY 628,417,660.68 at the end of Q1 2022, a decrease of about 22.9%[23] - Operating cash inflow for Q1 2023 was CNY 287,111,040.43, down from CNY 316,066,571.72 in Q1 2022, reflecting a decrease of about 9.2%[21] - The company invested CNY 97,838,674.51 in fixed assets and intangible assets during Q1 2023, compared to CNY 52,486,090.96 in Q1 2022, representing an increase of approximately 86.2%[22] Expenses and Liabilities - Total operating costs increased to CNY 262,441,239.37, up 22.5% from CNY 214,113,341.19 in Q1 2022[19] - Sales expenses rose by 40.64% to CNY 133,965,927.69, primarily due to increased employee compensation and meeting costs[9] - Total liabilities rose to CNY 250,015,468.98, up from CNY 230,634,015.20 at the beginning of the year[18] - The company reported a significant increase in contract liabilities to CNY 10,207,350.65, compared to CNY 2,005,290.19 in the previous period[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,961, with the largest shareholder, Liu Jidong, holding 28.59% of shares[11] - Liu Jidong holds 25,315,500 shares, with 18,986,625 shares under lock-up conditions and 3,530,000 shares pledged[11] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder holding 4.35%[11] - The company’s major shareholders do not hold shares through margin trading accounts[12] Research and Development - The company increased its R&D expenditure compared to the previous year, contributing to the decline in net profit[7] - Research and development expenses rose to CNY 28,684,039.18, an increase of 28.5% compared to CNY 22,312,058.34 in the previous year[19] - The company is actively expanding its product offerings and enhancing its technological capabilities through various certifications and approvals[16] Government Support and Certifications - The company reported a significant increase in government subsidies, with other income rising by 423.87% to CNY 5,064,032.46[9] - The company’s technology center has been recognized as a national enterprise technology center, eligible for tax benefits and policy support[14] - The subsidiary, Shenyang Xingqi Eye Hospital, has been certified as a high-tech enterprise, enjoying a reduced corporate income tax rate of 15% for three years[15] - The company’s product, Compound Electrolyte Eye Wash, has been included in the National Medical Insurance Directory[16] - The company has received a drug registration certificate for Sodium Hyaluronate Eye Drops, with approval number H20233348[16] - The company signed a project investment agreement with the Shenyang Free Trade Zone Management Committee, indicating ongoing investment activities[13] Audit Status - The company has not undergone an audit for the Q1 2023 report[24]